Related references
Note: Only part of the references are listed.Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia - response to Rider etal
Alexey V. Danilov
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
Candida Vitale et al.
HAEMATOLOGICA (2016)
Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia
S. Schliffke et al.
LEUKEMIA (2016)
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
Candida Vitale et al.
HAEMATOLOGICA (2016)
Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia
Sudhir Manda et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment
Kate Hodgson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Julie A. Di Paolo et al.
NATURE CHEMICAL BIOLOGY (2011)
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
Betty Y. Chang et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance
Carol Moreno et al.
BLOOD (2010)
Share Paper
